Abstract
Intravitreal triamcinolone and bevacizumab are emerging treatment modalities for the patients of macular oedema; however, they are known to raise intraocular pressure. A 61 year old diabetic male patient developed glaucoma after administration of triamcinolone acetonide and bevacizumab intravitreally for treatment of macular oedema. His intraocular pressure was raised up to about 42 mm Hg. Such high and sustained rise in intraocular pressure may lead to vision loss by damaging the optic nerve. The patient was managed by local as well as systematic therapy and was recovered after 1 month from the occurrence of an event. Intraocular pressure should be monitored in patients receiving intravitreal triamcinolone and bevacizumab. Risk benefit analysis must be done before using IVTA and IVB in patients with diabetic macular oedema.
Keywords: Triamcinolone acetonide, bevacizumab, intraocular pressure, diabetes mellitus, adverse drug reaction.
Current Drug Safety
Title:Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report
Volume: 11 Issue: 3
Author(s): Hiral N. Golakiya, Hiren N. Hirapara, Sugnesh J. Parmar, Viren N. Naik and Chandrabhanu B. Tripathi
Affiliation:
Keywords: Triamcinolone acetonide, bevacizumab, intraocular pressure, diabetes mellitus, adverse drug reaction.
Abstract: Intravitreal triamcinolone and bevacizumab are emerging treatment modalities for the patients of macular oedema; however, they are known to raise intraocular pressure. A 61 year old diabetic male patient developed glaucoma after administration of triamcinolone acetonide and bevacizumab intravitreally for treatment of macular oedema. His intraocular pressure was raised up to about 42 mm Hg. Such high and sustained rise in intraocular pressure may lead to vision loss by damaging the optic nerve. The patient was managed by local as well as systematic therapy and was recovered after 1 month from the occurrence of an event. Intraocular pressure should be monitored in patients receiving intravitreal triamcinolone and bevacizumab. Risk benefit analysis must be done before using IVTA and IVB in patients with diabetic macular oedema.
Export Options
About this article
Cite this article as:
Golakiya N. Hiral, Hirapara N. Hiren, Parmar J. Sugnesh, Naik N. Viren and Tripathi B. Chandrabhanu, Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report, Current Drug Safety 2016; 11 (3) . https://dx.doi.org/10.2174/1574886311666160405110246
DOI https://dx.doi.org/10.2174/1574886311666160405110246 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-angiogenic Drugs as an Adjunctive Therapy in the Surgical Treatment of Diabetic Retinopathy
Current Diabetes Reviews Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Topical Dermatological Drug Delivery: Quo Vadis?
Current Drug Delivery PEDF in Angiogenic Eye Diseases
Current Molecular Medicine Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy
Current Pharmaceutical Design Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Central Retinal Vein Occlusion: Current Therapeutic Approach
Vascular Disease Prevention (Discontinued) The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Fractional Moving Blood Volume Measurement Using Power Doppler Ultrasound as an Estimation of Fetal Organ Blood Perfusion
Current Medical Imaging Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine